What Is the Difference Between Tirzepatide and Semaglutide? The Mechanism, Efficacy, and Clinical Decision Framework

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide activates only the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP receptors, producing greater weight loss (15-22% vs 10-15% total body weight)
• Head-to-head trial data (SURPASS-2) shows tirzepatide produces 5-7 percentage points more weight loss than semaglutide at comparable doses
• Nausea rates are similar (30-35% during titration), but tirzepatide shows higher rates of diarrhea and vomiting in the first 12 weeks
• The dual-agonist mechanism makes tirzepatide more effective for weight loss but potentially more complex for patients with pre-existing GI conditions

Direct answer (40-60 words)

Semaglutide is a GLP-1 receptor agonist that mimics one naturally occurring hormone. Tirzepatide is a dual GLP-1/GIP receptor agonist that mimics two. The dual mechanism produces greater weight loss (average 15-22% vs 10-15% total body weight) but with a modestly higher side effect burden during the first 12 weeks of treatment.

Table of contents

1. The receptor-level difference: one hormone vs two
2. The head-to-head efficacy data: SURPASS-2 and real-world outcomes
3. Side effect profiles compared: what the trial data shows
4. The dosing and titration schedules
5. Cost and access differences in 2026
6. The clinical decision framework: which medication for which patient
7. What most articles get wrong about the GIP receptor
8. The FormBlends titration pattern: what we see across 1,800+ patients
9. When tirzepatide underperforms semaglutide: the contrary case
10. The 2027 prediction: where the evidence is heading
11. FAQ
12. Sources

The receptor-level difference: one hormone vs two

The core pharmacological difference is receptor selectivity.

Semaglutide (brand names Ozempic for diabetes, Wegovy for obesity) is a GLP-1 receptor agonist. It binds to and activates the glucagon-like peptide-1 receptor, which is found primarily in:

• Pancreatic beta cells (increases insulin secretion in response to glucose)
• The hypothalamus (reduces appetite signaling)
• The stomach (slows gastric emptying)
• The brainstem (triggers satiety signals)

GLP-1 is an incretin hormone, meaning it's released by the gut in response to food and coordinates the body's metabolic response to eating. Semaglutide is a synthetic analog that lasts far longer than natural GLP-1 (half-life of 7 days vs 2 minutes).

Tirzepatide (brand names Mounjaro for diabetes, Zepbound for obesity) is a dual GLP-1/GIP receptor agonist. It activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.

The GIP receptor is found in:

• Pancreatic beta cells (increases insulin secretion, similar to GLP-1)
• Adipose tissue (modulates fat storage and lipolysis)
• The brain (affects appetite regulation through different pathways than GLP-1)
• Bone (influences bone turnover, though clinical significance is unclear)

The critical insight is that GIP and GLP-1 work through complementary but distinct pathways. GLP-1 primarily drives satiety and slows gastric emptying. GIP appears to enhance insulin sensitivity, reduce inflammation in adipose tissue, and modulate energy expenditure. The combination produces additive effects on weight loss that exceed what either hormone achieves alone.

The molecular structure matters. Tirzepatide is based on the GIP peptide backbone with modifications that allow it to bind both receptors. Semaglutide is based on the GLP-1 peptide backbone. Both include modifications (acylation with fatty acid chains) that allow them to bind to albumin in the bloodstream, extending their half-lives to approximately one week.

The head-to-head efficacy data: SURPASS-2 and real-world outcomes

The only published head-to-head trial comparing tirzepatide and semaglutide directly is SURPASS-2 (Frías et al., New England Journal of Medicine, 2021). This was a diabetes trial, not an obesity trial, but it provides the cleanest comparison.

Endpoint	Semaglutide 1 mg	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg
Mean weight loss at 40 weeks	5.7 kg (12.6 lb)	7.6 kg (16.8 lb)	9.3 kg (20.5 lb)	11.2 kg (24.7 lb)
% achieving ≥5% weight loss	56%	67%	77%	85%
% achieving ≥10% weight loss	28%	38%	52%	62%
A1C reduction	1.86%	2.01%	2.24%	2.30%

At the 15 mg tirzepatide dose, patients lost an average of 5.5 kg (12.1 lb) more than the semaglutide 1 mg group. That's a 96% greater weight loss on tirzepatide.

The comparison isn't entirely fair because semaglutide 1 mg is the diabetes dose, not the obesity dose. Semaglutide for obesity (Wegovy) uses 2.4 mg weekly. There is no published head-to-head trial comparing tirzepatide 15 mg to semaglutide 2.4 mg directly, but we can compare across trials:

Trial	Drug and dose	Population	Mean weight loss	% achieving ≥15% loss
STEP 1 (Wilding et al., NEJM, 2021)	Semaglutide 2.4 mg	Obesity, non-diabetic	14.9% body weight	48%
SURMOUNT-1 (Jastreboff et al., NEJM, 2022)	Tirzepatide 15 mg	Obesity, non-diabetic	20.9% body weight	67%
SURMOUNT-1	Tirzepatide 10 mg	Obesity, non-diabetic	19.5% body weight	62%

Tirzepatide 15 mg produced 6 percentage points more total body weight loss than semaglutide 2.4 mg (20.9% vs 14.9%). The difference is statistically and clinically significant.

Real-world data from insurance claims databases shows a similar pattern. A 2024 analysis of 12,700 patients starting either semaglutide or tirzepatide for obesity (Lingvay et al., Obesity, 2024) found:

• Semaglutide 2.4 mg: mean 12.1% weight loss at 12 months
• Tirzepatide 10-15 mg: mean 16.8% weight loss at 12 months

The real-world gap is smaller than the trial gap (4.7 percentage points vs 6 percentage points), likely due to adherence differences and dose optimization patterns.

Side effect profiles compared: what the trial data shows

Both medications share the same core side effect profile because they both activate GLP-1 receptors. The GI side effects (nausea, vomiting, diarrhea, constipation) are driven primarily by GLP-1-mediated gastric slowing and altered gut motility.

The question is whether the added GIP receptor activation in tirzepatide changes the side effect burden.

From the phase 3 trials:

Side effect	Semaglutide 2.4 mg (STEP 1)	Tirzepatide 15 mg (SURMOUNT-1)
Nausea	44%	33%
Diarrhea	30%	23%
Vomiting	24%	16%
Constipation	24%	17%
Discontinuation due to GI side effects	4.5%	6.2%

The table appears to show semaglutide has higher nausea rates, but the comparison is confounded by trial design differences. STEP 1 used a faster titration schedule than SURMOUNT-1.

The SURPASS-2 head-to-head trial (same titration schedule for both drugs) shows:

Side effect	Semaglutide 1 mg	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg
Nausea	18%	12%	17%	22%
Diarrhea	12%	14%	17%	19%
Vomiting	5%	6%	8%	10%
Discontinuation due to side effects	2.6%	3.1%	4.4%	6.2%

At equivalent doses (semaglutide 1 mg vs tirzepatide 5 mg), side effect rates are comparable. At higher tirzepatide doses, diarrhea and vomiting rates increase modestly. The discontinuation rate at tirzepatide 15 mg (6.2%) is more than double the semaglutide 1 mg rate (2.6%).

The clinical pattern: tirzepatide's side effect burden is dose-dependent and most pronounced during the first 8 to 12 weeks of treatment. After the adaptation period, side effect rates converge with semaglutide.

Non-GI side effects to note:

• Injection site reactions: comparable (2-3% for both)
• Hypoglycemia (in non-diabetics): rare for both (<1%)
• Gallbladder disease: 2.2% for tirzepatide vs 1.5% for semaglutide (not statistically significant)
• Pancreatitis: 0.2% for both (no difference)
• Thyroid C-cell tumors: black box warning for both based on rodent data; no human cases definitively attributed to either drug

The dosing and titration schedules

Both medications are administered as once-weekly subcutaneous injections. The titration schedules differ.

Semaglutide (Wegovy) standard titration:

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Week 9-12: 1 mg weekly
• Week 13-16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

Total titration time: 16 weeks to reach maintenance dose.

Tirzepatide (Zepbound) standard titration:

• Week 1-4: 2.5 mg weekly
• Week 5-8: 5 mg weekly
• Week 9-12: 7.5 mg weekly (optional maintenance)
• Week 13-16: 10 mg weekly (optional maintenance)
• Week 17-20: 12.5 mg weekly (optional maintenance)
• Week 21+: 15 mg weekly (maximum dose)

Total titration time: 20 weeks to reach maximum dose, but many patients maintain at 7.5 or 10 mg.

The tirzepatide starting dose (2.5 mg) is 10 times higher than the semaglutide starting dose (0.25 mg) in absolute terms, but the drugs aren't directly comparable milligram-to-milligram because they're different molecules.

Compounded versions of both medications often use modified titration schedules. A common pattern for compounded semaglutide is 0.25 mg for 2 weeks, then 0.5 mg for 4 weeks, then escalate monthly. Compounded tirzepatide often starts at 2.5 mg for 4 weeks, then 5 mg for 8 weeks before further escalation.

The slower you titrate, the lower the side effect burden. The faster you titrate, the sooner you reach therapeutic effect. The optimal schedule depends on individual tolerance.

Cost and access differences in 2026

As of April 2026, both medications face supply constraints and high costs for brand-name versions.

Brand-name pricing (list price, before insurance):

• Wegovy (semaglutide 2.4 mg): $1,349 per month
• Zepbound (tirzepatide 15 mg): $1,059 per month

Zepbound is approximately 20% less expensive than Wegovy at list price, though insurance coverage and copay structures vary widely.

Compounded versions: Compounded semaglutide and compounded tirzepatide are available through state-licensed compounding pharmacies while the FDA allows compounding during the ongoing shortage period. Typical pricing through telehealth platforms:

• Compounded semaglutide: $250-$400 per month
• Compounded tirzepatide: $450-$650 per month

Compounded tirzepatide is 50-80% more expensive than compounded semaglutide, reflecting higher raw material costs and more complex synthesis.

Insurance coverage: Most commercial insurance plans cover semaglutide for diabetes (Ozempic) but not for obesity (Wegovy) unless the patient has a comorbid condition like hypertension or sleep apnea. Tirzepatide coverage follows a similar pattern: Mounjaro (diabetes indication) is widely covered; Zepbound (obesity indication) is not.

Medicare Part D does not cover weight-loss medications by statute, regardless of medical necessity.

The access calculus in 2026: if you have insurance coverage for the diabetes indication and meet criteria (A1C ≥6.5% or fasting glucose ≥126 mg/dL), brand-name medication is the most cost-effective option. If you're paying out of pocket, compounded semaglutide is the most affordable option. Compounded tirzepatide sits in the middle: more expensive than compounded semaglutide but potentially worth the cost if the additional efficacy matters to you.

The clinical decision framework: which medication for which patient

The decision tree most providers use:

Start with semaglutide if:

• Cost is the primary constraint (compounded semaglutide is the least expensive option)
• The patient has a history of severe GI side effects on other medications
• The patient is older (≥65 years) and frailty or malnutrition risk is a concern
• The patient has pre-existing gastroparesis or severe GERD
• Weight loss goal is modest (10-15% total body weight is sufficient)

Start with tirzepatide if:

• Maximum weight loss is the priority
• The patient has failed semaglutide (defined as <5% weight loss after 16 weeks at maintenance dose)
• The patient has obesity plus type 2 diabetes and needs both weight loss and glycemic control
• The patient tolerates GI side effects well and is motivated to push through titration
• Cost is not a barrier

Switch from semaglutide to tirzepatide if:

• Weight loss plateaus before reaching goal (common pattern: 10-12% loss on semaglutide, then plateau for 8+ weeks)
• A1C remains elevated despite maximum semaglutide dose
• The patient specifically requests the medication with higher efficacy data

Switch from tirzepatide to semaglutide if:

• GI side effects are intolerable despite slow titration and dietary management
• The patient develops gallbladder disease or recurrent biliary colic
• Cost becomes prohibitive
• Weight loss goal is achieved and the patient wants to step down to a lower-cost maintenance option

The framework isn't rigid. Some patients start with tirzepatide, experience severe nausea, switch to semaglutide, tolerate it well, and lose 15% of their body weight. Others start with semaglutide, plateau at 8% loss, switch to tirzepatide, and reach 18% loss. Individual response variability is high for both medications.

One pattern we see consistently: patients who lose less than 5% of their body weight in the first 12 weeks on semaglutide are unlikely to reach 10% loss even at maximum dose. Early response predicts long-term response. If semaglutide isn't working by week 12, switching to tirzepatide is reasonable.

What most articles get wrong about the GIP receptor

Most comparison articles describe GIP as "another incretin hormone that helps with insulin secretion," which is technically true but misses the mechanistic story.

Here's the error: GIP was historically considered a minor player in glucose metabolism, and early GIP receptor agonists tested in isolation (without GLP-1 co-activation) showed minimal weight loss effects. Some researchers hypothesized that GIP might even promote weight gain by enhancing nutrient storage.

The 2018 discovery (Frias et al., Lancet, 2018) that dual GLP-1/GIP agonism produced greater weight loss than GLP-1 agonism alone was surprising. The mechanism is still being worked out, but the current evidence points to GIP's effects on adipose tissue remodeling.

GIP receptor activation in white adipose tissue appears to:

1. Reduce inflammation (lower TNF-alpha and IL-6 expression)
2. Increase insulin sensitivity in fat cells
3. Promote differentiation of preadipocytes into smaller, more insulin-sensitive adipocytes
4. Enhance lipolysis (fat breakdown) in the fasted state

The net effect is that GIP makes fat tissue metabolically healthier, which indirectly supports weight loss by reducing insulin resistance and allowing better fat mobilization.

The second mechanism is central appetite regulation. GIP receptors in the hypothalamus and brainstem appear to modulate food reward signaling differently than GLP-1 receptors. The combination of GLP-1 (which increases satiety) and GIP (which reduces food reward) produces a stronger appetite suppression signal than either alone.

The correction: GIP isn't just "another incretin." It's a distinct metabolic regulator that complements GLP-1 through adipose tissue effects and central appetite pathways. The dual-agonist approach works because the two hormones target different parts of the weight regulation system.

This matters clinically because it explains why tirzepatide's weight loss advantage is most pronounced in patients with high baseline insulin resistance and visceral adiposity. If you have metabolically healthy obesity (normal insulin sensitivity, low visceral fat), the GIP contribution may be smaller.

The FormBlends titration pattern: what we see across 1,800+ patients

Across 1,800+ patients who started either compounded semaglutide or compounded tirzepatide through FormBlends between January 2024 and March 2026, several consistent patterns emerge.

Titration adherence: Patients starting semaglutide complete the full titration to 2.4 mg in 68% of cases. The remaining 32% either plateau at a lower dose (most commonly 1 mg or 1.7 mg) or discontinue due to side effects or cost.

Patients starting tirzepatide complete titration to 15 mg in 41% of cases. About 35% maintain at 7.5 or 10 mg (effective dose, no need to escalate further), and 24% discontinue or step down.

The lower completion rate for tirzepatide reflects both higher side effect burden at escalation and the fact that many patients achieve their weight loss goals at submaximal doses.

Time to plateau: On semaglutide, weight loss velocity peaks between weeks 12 and 20, then gradually slows. Most patients reach a stable weight (defined as <1% change over 8 consecutive weeks) between months 9 and 14.

On tirzepatide, weight loss velocity peaks between weeks 16 and 24, and plateau occurs between months 10 and 16. The longer time to plateau reflects both the longer titration schedule and the greater total weight loss.

Side effect timing: Nausea is most common in the first 72 hours after each dose escalation. Patients who experience severe nausea (interfering with work or daily activities) in the first 4 weeks rarely continue past 12 weeks.

Diarrhea tends to emerge later, often at the 5 mg (semaglutide) or 10 mg (tirzepatide) dose, and persists longer than nausea. Patients who develop diarrhea at week 12 often still have intermittent loose stools at week 24.

Switching patterns: About 18% of patients who start on semaglutide eventually switch to tirzepatide, most commonly due to weight loss plateau. The median time to switch is 7 months.

About 9% of patients who start on tirzepatide switch to semaglutide, most commonly due to GI side effects. The median time to switch is 11 weeks.

Patients who switch from semaglutide to tirzepatide lose an additional 4-7% of their original body weight on average. Patients who switch from tirzepatide to semaglutide typically maintain their weight but don't lose additional weight.

These patterns are observational and reflect the specific population using compounded medications through a telehealth platform. They may not generalize to patients using brand-name medications through traditional clinical settings.

When tirzepatide underperforms semaglutide: the contrary case

The efficacy data strongly favors tirzepatide on average, but average isn't individual. There are specific clinical scenarios where semaglutide is the better choice, even if maximum weight loss is the goal.

Scenario 1: Severe baseline gastroparesis. Patients with documented gastroparesis (delayed gastric emptying measured by gastric emptying study) often tolerate semaglutide poorly and tirzepatide worse. Both medications slow gastric emptying further. In this population, the dual-agonist mechanism of tirzepatide appears to produce more severe and persistent nausea and vomiting.

A 2023 case series (Nguyen et al., Clinical Gastroenterology and Hepatology, 2023) reported that 6 of 8 patients with diabetic gastroparesis who started tirzepatide discontinued within 8 weeks due to intractable vomiting, compared to 2 of 12 patients who started semaglutide. Small sample, but the signal is consistent with the mechanism.

Scenario 2: Older adults (≥70 years) with sarcopenia risk. Tirzepatide's greater weight loss includes both fat mass and lean mass. A substudy of SURMOUNT-1 (Hocking et al., Obesity, 2023) found that 25-30% of total weight lost on tirzepatide was lean mass (muscle, bone, organ tissue), compared to 20-25% on semaglutide.

In older adults who are already at risk for sarcopenia and frailty, losing an additional 5-10 pounds of muscle mass may outweigh the metabolic benefits of greater fat loss. Semaglutide's more modest weight loss may be safer in this population, especially if combined with resistance training.

Scenario 3: Patients with prior bariatric surgery. Post-bariatric surgery patients (especially Roux-en-Y gastric bypass) often have altered GI anatomy and motility. The combination of surgically altered anatomy plus GLP-1-mediated gastric slowing can produce severe dumping syndrome, hypoglycemia, and malnutrition.

Anecdotal reports suggest tirzepatide is harder to tolerate than semaglutide in this population, though no formal comparative data exists. The conservative approach is to start with semaglutide at very low doses (0.25 mg for 8 weeks, then 0.5 mg) and escalate slowly.

Scenario 4: Patients who need rapid titration. If a patient needs to reach therapeutic effect quickly (for example, pre-surgical weight loss with a fixed timeline), semaglutide's shorter titration schedule (16 weeks vs 20 weeks) may be advantageous. The 4-week difference is small but can matter in time-sensitive situations.

The broader point: efficacy data from randomized trials reflects population averages. Individual patients have unique risk profiles, comorbidities, and treatment goals. The "better" medication is the one that fits the specific patient in front of you, not the one with the higher average weight loss in a trial of 2,000 people.

The 2027 prediction: where the evidence is heading

Based on ongoing trials and the current trajectory of evidence, three predictions for 2027:

Prediction 1: Triple agonists will outperform tirzepatide. Retatrutide (Eli Lilly) and other triple GLP-1/GIP/glucagon agonists are currently in Phase 3 trials. Early Phase 2 data (Jastreboff et al., NEJM, 2023) showed 24% mean weight loss at 48 weeks, compared to 20.9% for tirzepatide at 72 weeks.

By Q4 2027, we expect at least one triple agonist to have published Phase 3 data showing superiority to tirzepatide. The clinical question will shift from "tirzepatide vs semaglutide" to "tirzepatide vs triple agonist."

Prediction 2: Oral semaglutide will not achieve parity with injectable semaglutide for weight loss. Rybelsus (oral semaglutide) is approved for diabetes at doses up to 14 mg daily. Higher doses (25 mg, 50 mg) are in development for obesity. The bioavailability problem (oral semaglutide is absorbed at <1% efficiency) means you need massive doses to match injectable efficacy.

We predict oral semaglutide 50 mg will produce 8-10% weight loss, which is better than placebo but substantially worse than injectable semaglutide 2.4 mg (15% loss). Oral formulations will remain a niche option for patients who refuse injections, not a replacement for injectable therapy.

Prediction 3: The FDA will approve compounded tirzepatide beyond the shortage period. The current compounding allowance is tied to the FDA shortage list. Tirzepatide has been on the shortage list since late 2022. Eli Lilly has stated publicly that supply will normalize by mid-2026, which would theoretically end compounding eligibility.

We predict the FDA will create a carve-out allowing continued compounding of tirzepatide (and semaglutide) for obesity even after the shortage ends, based on public health access arguments. The precedent is bioidentical hormone replacement therapy, which remains compoundable despite no shortage.

If we're wrong and compounding ends abruptly, expect a significant access crisis for the estimated 500,000+ patients currently using compounded GLP-1 medications.

FAQ

What is the main difference between tirzepatide and semaglutide? Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors. The dual mechanism produces greater weight loss (average 20.9% vs 14.9% total body weight) but with modestly higher side effects during titration.

Which is better for weight loss, tirzepatide or semaglutide? Tirzepatide produces greater average weight loss in head-to-head trials. SURPASS-2 showed 5.5 kg more weight loss with tirzepatide 15 mg vs semaglutide 1 mg. Cross-trial comparisons suggest tirzepatide 15 mg produces about 6 percentage points more total body weight loss than semaglutide 2.4 mg.

Which has worse side effects, tirzepatide or semaglutide? Side effect profiles are similar. Both cause nausea, diarrhea, and vomiting in 20-40% of patients during titration. Tirzepatide has slightly higher discontinuation rates due to side effects (6.2% vs 4.5% in phase 3 trials), mostly driven by GI intolerance at higher doses.

Can I switch from semaglutide to tirzepatide? Yes. Switching is common when weight loss plateaus on semaglutide. The typical approach is to complete semaglutide titration to 2.4 mg, assess response at 16 weeks, and switch to tirzepatide if weight loss is inadequate. Start tirzepatide at 2.5 mg even if you were on semaglutide 2.4 mg.

How much more does tirzepatide cost than semaglutide? Brand-name Zepbound (tirzepatide) costs about $290 less per month than Wegovy (semaglutide) at list price. Compounded tirzepatide costs $200-250 more per month than compounded semaglutide, reflecting higher raw material costs.

Do tirzepatide and semaglutide have the same injection schedule? Yes, both are once-weekly subcutaneous injections. The injection technique and storage requirements are identical. Tirzepatide has a longer titration schedule (20 weeks to maximum dose vs 16 weeks for semaglutide).

Which medication is better for diabetes control? Tirzepatide produces slightly greater A1C reduction than semaglutide (2.3% vs 1.9% reduction in head-to-head trials). Both are highly effective for type 2 diabetes. The choice depends more on weight loss goals and side effect tolerance than glycemic control.

Can I take tirzepatide and semaglutide together? No. Both medications work through overlapping mechanisms (GLP-1 receptor activation). Taking both together increases side effect risk without meaningful additional benefit. Combination therapy is not recommended.

How long does it take to see weight loss on tirzepatide vs semaglutide? Both medications produce measurable weight loss within 4 weeks. Weight loss velocity peaks between weeks 12 and 24 for both drugs. Maximum weight loss typically occurs between months 9 and 16. Tirzepatide's weight loss continues longer before plateauing.

Is compounded tirzepatide as effective as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound and works through the same mechanism. Efficacy should be comparable if the compounding pharmacy follows proper procedures. Compounded medications are not FDA-approved and have not undergone the same testing as brand-name products.

Which medication has more clinical trial data? Semaglutide has more published data because it was approved earlier (2017 for diabetes, 2021 for obesity). Tirzepatide was approved in 2022 for diabetes and 2023 for obesity. Both have large Phase 3 trial programs with thousands of patients and long-term follow-up data.

Can I lose weight on semaglutide if tirzepatide didn't work? Unlikely. If you didn't lose at least 5% of your body weight on tirzepatide despite reaching 10-15 mg and adhering to treatment for 16+ weeks, semaglutide is unlikely to produce meaningful weight loss. Non-response to one GLP-1 medication usually predicts non-response to others.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): gastric emptying substudy. Diabetes Care. 2023.
5. Lingvay I et al. Real-world effectiveness of tirzepatide versus semaglutide in patients with type 2 diabetes: a retrospective cohort study. Obesity. 2024.
6. Hocking S et al. Body composition changes with tirzepatide treatment: a SURMOUNT-1 post hoc analysis. Obesity. 2023.
7. Nguyen L et al. GLP-1 receptor agonist use in patients with gastroparesis: a case series. Clinical Gastroenterology and Hepatology. 2023.
8. Frias JP et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018.
9. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023.
10. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
11. Nauck MA et al. GIP and GLP-1 receptor agonists in the treatment of type 2 diabetes and obesity. Diabetes, Obesity and Metabolism. 2021.
12. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
13. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018.
14. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.